Metastasectomy for gastrointestinal stromal tumors

Journal of Surgical Oncology

Volumn 109, Issue 1, 2014, Pages 23-27

  Bamboat, Zubin M ^a   Dematteo, Ronald P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

gastrointestinal stromal tumor; KIT; metastasectomy; tyrosine kinase

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; IMATINIB;

CANCER SURVIVAL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; METASTASIS; METASTASIS RESECTION; MOLECULAR PATHOLOGY; MUTATION; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

GASTROINTESTINAL STROMAL TUMOR; KIT; METASTASECTOMY; TYROSINE KINASE;

BENZAMIDES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; METASTASECTOMY; MUTATION; PATIENT SELECTION; PIPERAZINES; PYRIMIDINES;

EID: 84890562246     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23451     Document Type: Review

References (38)

1. Dagher R, Cohen M, Williams G, et al.: Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002; 8: 3034-3038.
2. Dematteo RP, Ballman KV, Antonescu CR, et al.: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104.
3. Blanke CD, Demetri GD, von Mehren M, et al.: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-625.
4. Gold JS, van der Zwan SM, Gonen M, et al.: Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 2007; 14: 134-142.
5. Crosby JA, Catton CN, Davis A, et al.: Malignant gastrointestinal stromal tumors of the small intestine: A review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8: 50-59.
6. Joensuu H, Fletcher C, Dimitrijevic S, et al.: Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3: 655-664.
7. Dematteo RP, Heinrich MC, El-Rifai WM, et al.: Clinical management of gastrointestinal stromal tumors: Before and after STI-571. Hum Pathol 2002; 33: 466-477.
8. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
9. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
10. Blanke CD, Rankin C, Demetri GD, et al.: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632.
11. Verweij J, Casali PG, Zalcberg J, et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127-1134.
12. Debiec-Rychter M, Sciot R, Le Cesne A, et al.: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103.
13. Van Glabbeke M, Verweij J, Casali PG, et al.: Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 2006; 42: 2277-2285.
14. Blay JY, Le Cesne A, Ray-Coquard I, et al.: Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113.
15. Demetri GD, von Mehren M, Antonescu CR, et al.: NCCN Task Force report: Update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8: S1-S41, quiz S42-S44.
16. DeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
17. van Oosterom AT, Judson I, Verweij J, et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 2001; 358: 1421-1423.
18. Scaife CL, Hunt KK, Patel SR, et al.: Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate ? Am J Surg 2003; 186: 665-669.
19. Bauer S, Hartmann JT, de Wit M, et al.: Resection of residual disease in patients with metastatic gastrointestinal stromal. Int J Cancer 2005; 117: 316-325.
20. Antonescu CR, Besmer P, Guo T:, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-4190.
21. Raut CP, Posner M, Desai J, et al.: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325-2331.
22. DeMatteo RP, Maki RG, Singer S, et al.: Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245: 347-352.
23. Rutkowski P, Nowecki Z, Nyckowski P, et al.: Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304-311.
24. Andtbacka RH, Ng CS, Scaife CL, et al.: Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14-24.
25. Sym SJ, Ryu MH, Lee JL, et al.: Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol 2008; 98: 27-33.
26. Gronchi A, Fiore M, Miselli F, et al.: Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007; 245: 341-346.
27. Xia L, Zhang MM, Ji L, et al.: Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today 2010; 40: 936-942.
28. Wang D, Zhang Q, Blanke CD, et al.: Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 2012; 19: 1074-1080.
29. Raut CP, Wang Q, Manola J, et al.: Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol 2010; 17: 407-415.
30. Heinrich MC, Owzar K, Corless CL, et al.: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360-5367.
31. Debiec-Rychter M, Wasag B, Stul M, et al.: Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004; 202: 430-438.
32. Lasota J, Corless CL, Heinrich MC, et al.: Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: A multicenter study on 54 cases. Mod Pathol 2008; 21: 476-484.
33. Heinrich MC, Maki RG, Corless CL, et al.: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 5352-5359.
34. Pawlik TM, Vauthey JN, Abdalla EK, et al.: Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006; 141: 537-543, discussion 543-544.
35. Maluccio MA, Covey AM, Schubert J, et al.: Treatment of metastatic sarcoma to the liver with bland embolization. Cancer 2006; 107: 1617-1623.
36. Ye YJ, Gao ZD, Poston GJ, et al.: Diagnosis and multi-disciplinary management of hepatic metastases from gastrointestinal stromal tumour (GIST). Eur J Surg Oncol 2009; 35: 787-792.
37. Karakousis GC, Singer S, Zheng J, et al.: Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): A size-matched comparison. Ann Surg Oncol 2011; 18: 1599-1605.
38. Nishimura J, Nakajima K, Omori T, et al.: Surgical strategy for gastric gastrointestinal stromal tumors: Laparoscopic vs. open resection. Surg Endosc 2007; 21: 875-878.